SCHEDULE: Morgan Stanley Exits Major BiomX Stake

Morgan Stanley and its subsidiary have reported ceasing beneficial ownership of more than five percent of BiomX Inc.'s common stock.

Summary

• Morgan Stanley and Morgan Stanley & Co. LLC have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in BiomX Inc.
• As of July 31, 2025, both Morgan Stanley and Morgan Stanley & Co. LLC ceased to be beneficial owners of more than five percent of BiomX Inc.'s Common Stock.
• Their aggregate beneficial ownership is now reported as 0.00 shares, representing 0.0% of the class of securities.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine regulatory filing disclosing a change in beneficial ownership below the reporting threshold, with no direct positive or negative implications for the issuer's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding BiomX Inc.'s future performance or operations.

Industry Context

This filing reflects a routine disclosure of a change in institutional ownership, specifically a reduction below the 5% reporting threshold. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• This filing primarily impacts investors who track institutional ownership, indicating a major financial institution has reduced its stake below the 5% threshold. It does not directly impact employees, customers, suppliers, or creditors of BiomX Inc.

Key Dates

Keywords

BiomX Inc., Morgan Stanley, Schedule 13G, beneficial ownership, common stock, institutional ownership, SEC filing